ESMO-MCBS
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
ESMO GI 2024 Scientific Committee members and GI experts give their reasons why you should not miss this important event.
The current state of the art in lung cancer therapy
How to apply the latest, best practice recommendations to your daily practice? Join this live discussion and have your questions answered by the ESMO Guidelines experts
Innovative Approaches in Head and Neck Oncology
Registration for the ESMO Academy 2024 is now open. Get your update on the key topics in medical oncology.
Present your latest cancer research to the widest possible audience in our live, online sessions
Understand the clinical and scientific applications of the molecular tumour boards for different methodologies in tumour sequencing.
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Online application is open until 27 March 2024
Online application is open until 19 March 2024
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients
ESMO is sustaining its efforts to give rare cancers a more prominent place in oncology
Innovative models and increased cross-border collaborations can further support the implementation of rare cancer reference centres to expedite diagnosis and improve treatment
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalise treatments in the first-line as a study suggests
A study shows that early kinetics in DNA methylation and fragment quantity in plasma can predict response to pembrolizumab in patients with advanced solid tumours
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Findings from the ECLIPSE and BLUE-C studies
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Evidence for efficacy is based on the results from the CheckMate 901 study
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients
ESMO is sustaining its efforts to give rare cancers a more prominent place in oncology
Innovative models and increased cross-border collaborations can further support the implementation of rare cancer reference centres to expedite diagnosis and improve treatment
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
Findings from the final distant metastasis-free survival analysis of KEYNOTE-716 study
Findings from the ECLIPSE and BLUE-C studies
Evidence for efficacy is based on the results from the CheckMate 901 study
Findings from the final distant metastasis-free survival analysis of KEYNOTE-716 study
It is indicated in adult patients at high risk for recurrence
Findings from the FIRSTMAPPP study
Findings from the EV-302 study
Evidence for efficacy is based on the results from the PAPILLON study
Findings from the analysis of SYNCHRONOUS and CCRe-IV studies
Findings from the D-TORCH study
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
Experts predict death rates from all cancers for the EU and UK for 2024
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
ESMO is pleased to announce the renewal of its status as non-State actor in official relations with the World Health Organization - a privilege granted to non-governmental organisations, which recognises ESMO’s sustained and systematic engagement in the interest of the WHO
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
As the world observes Universal Health Coverage Day, ESMO anticipates the results of the latest study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines, highlighting a worrying stall over the last five years
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.